AstraZeneca adapting vaccine for new Covid-19 strains as profits double

Drugs giant AstraZeneca confirmed it is focusing efforts on adapting its Covid-19 vaccine developed with Oxford University to new strains of the disease, as it revealed that annual profits more than doubled.